BioNTech (NASDAQ:BNTX) Price Target Cut to $122.00 by Analysts at TD Cowen

BioNTech (NASDAQ:BNTX) had its target price decreased by TD Cowen from $132.00 to $122.00 in a research report sent to investors on Tuesday, Benzinga reports. TD Cowen currently has a hold rating on the stock.

BNTX has been the subject of several other research reports. Bank of America raised their target price on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research report on Monday, September 16th. UBS Group upped their target price on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. HSBC lifted their price target on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. cut their target price on shares of BioNTech from $125.00 to $124.00 and set a “neutral” rating for the company in a research note on Monday. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, BioNTech presently has an average rating of “Moderate Buy” and an average price target of $134.69.

BioNTech Trading Up 1.8 %

Shares of BioNTech stock opened at $110.97 on Tuesday. BioNTech has a 52-week low of $76.53 and a 52-week high of $131.49. The firm has a market capitalization of $26.39 billion, a PE ratio of -49.10 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.54 and a quick ratio of 7.40. The company’s fifty day moving average price is $110.15 and its two-hundred day moving average price is $96.06.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.73 earnings per share. On average, analysts expect that BioNTech will post -2.93 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in BNTX. Victory Capital Management Inc. acquired a new stake in shares of BioNTech during the 3rd quarter worth approximately $345,000. Baillie Gifford & Co. grew its holdings in BioNTech by 0.4% during the 3rd quarter. Baillie Gifford & Co. now owns 8,308,071 shares of the company’s stock worth $986,750,000 after acquiring an additional 31,773 shares during the period. GSA Capital Partners LLP bought a new stake in shares of BioNTech during the 3rd quarter valued at $373,000. Arlington Capital Management Inc. lifted its stake in shares of BioNTech by 46.4% in the 3rd quarter. Arlington Capital Management Inc. now owns 3,807 shares of the company’s stock valued at $452,000 after purchasing an additional 1,207 shares during the period. Finally, Lodestone Wealth Management LLC bought a new position in shares of BioNTech in the 3rd quarter worth $8,373,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.